Carol Brosgart

11.1k citations

89 papers · 7.8k indexed · 3 hit papers · h-index 35

Epidemiology top 0.1%
Hepatology top 0.05%
Infectious Diseases top 0.5%
Virology top 2%
Surgery

Co-authors: Shelly Xiong Patrick Marcellin Seng Gee Lim Zachary Goodman John Fry Stephanos J. Hadziyannis Michael Wulfsohn E. Jenny Heathcote
Topics: Hepatitis B Virus Studies (75 papers)Hepatitis C virus research (73 papers)Liver Disease Diagnosis and Treatment (35 papers)
Cited by: Hepatology Epidemiology Infectious Diseases
Journals: New England Journal of Medicine The Lancet Gastroenterology
Partner nations: United States France Canada

In The Last Decade

Carol Brosgart

85 papers receiving 7.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis B

2003 1.0k citations Patrick Marcellin, Ting‐Tsung Chang et al. New England Journal of Medicine profile →
Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis B

2003 749 citations Stephanos J. Hadziyannis, Nicolaos C. Tassopoulos et al. New England Journal of Medicine profile →
Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years

2006 703 citations Stephanos J. Hadziyannis, Nicolaos C. Tassopoulos et al. Gastroenterology profile →

Peers

Countries citing papers authored by Carol Brosgart

Since Specialization

Citations

This map shows the geographic impact of Carol Brosgart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carol Brosgart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carol Brosgart more than expected).

Fields of papers citing papers by Carol Brosgart

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carol Brosgart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carol Brosgart. The network helps show where Carol Brosgart may publish in the future.

Co-authorship network of co-authors of Carol Brosgart

This figure shows the co-authorship network connecting the top 25 collaborators of Carol Brosgart. A scholar is included among the top collaborators of Carol Brosgart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carol Brosgart. Carol Brosgart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Test All for Hepatitis B Virus 2023 ·Clinics in Liver Disease ·(unknown),(unknown),(unknown),(unknown),Robert G. Gish,Carol Brosgart	2
2	An Updated Assessment of Chronic Hepatitis B Prevalence Among Foreign‐Born Persons Living in the United States 2021 ·Hepatology ·Robert J. Wong,Carol Brosgart,(unknown),(unknown),Mark Chen,Chari Cohen,W. Ray Kim,Kris V. Kowdley,Anna S. Lok,Naoky Tsai,John Ward,(unknown),Robert G. Gish	93
3	Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance 2011 ·Hepatology International ·Robert P. Perrillo,Hie-Won Hann,Eugene R. Schiff,David Mutimer,Bernard Willems,Nancy Leung,William M. Lee,(unknown),Mary Woessner,Carol Brosgart,Lynn D. Condreay,Stephen D. Gardner	11
4	Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin 2011 ·Hepatology ·Kris V. Kowdley,Chia C. Wang,(unknown),Henry Roberts,Carol Brosgart	310
5	Trends in Waiting List Registration for Liver Transplantation for Viral Hepatitis in the United States 2009 ·Gastroenterology ·W. Ray Kim,Norah A. Terrault,Rachel Pedersen,Terry M. Therneau,Erick Edwards,(unknown),Carol Brosgart	106
6	Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B 2008 ·Journal of Hepatology ·Joseph J.�Y. Sung,(unknown),Stefan Zeuzem,(unknown),E. Jenny Heathcote,Robert P. Perrillo,Carol Brosgart,Mary Woessner,(unknown),DF Gray,Stephen D. Gardner	117
7	508 48 Weeks of adefovir mono therapy following 48 weeks of combination therapy with peginterferon alpha-2b and adefovir leads to additional biochemical and virological improvement 2006 ·Journal of Hepatology ·Marc Lütgehetmann,Karsten Wursthorn,Peter Buggisch,Bernhard Zöllner,M Zankel,C Fischer,Carol Brosgart,J. Petersen	1
8	Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Yearsbreakdown → 2006 ·Gastroenterology ·Stephanos J. Hadziyannis,Nicolaos C. Tassopoulos,E. Jenny Heathcote,Ting‐Tsung Chang,G. Kitis,Mario Rizzetto,Patrick Marcellin,Seng Gee Lim,Zachary Goodman,Jia Ma,Carol Brosgart,Katyna Borroto–Esoda,Sarah Arterburn,Steven L. Chuck	703
9	Long-Term Therapy with Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B 2005 ·New England Journal of Medicine ·Stephanos J. Hadziyannis,Nicolaos C. Tassopoulos,E. Jenny Heathcote,Ting‐Tsung Chang,G. Kitis,Mario Rizzetto,Patrick Marcellin,Seng Gee Lim,Zachary Goodman,Jia Ma,Sarah Arterburn,Shelly Xiong,Graeme Currie,Carol Brosgart	407
10	Long-term (3-year) Therapy with Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen Negative Chronic Hepatitis B 2005 ·New England Journal of Medicine ·Stephanos J. Hadziyannis,N.C. Tassopoulos,E. Jenny Heathcote,Ting‐Tsung Chang,G. Kitis,Mario Rizzetto,Patrick Marcellin,Seng Gee Lim,(unknown),Jingqun Ma,Sarah Arterburn,Shanshan Xiong,Graeme P. Currie,Carol Brosgart	9
11	Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: Two double-blind, randomized, placebo-controlled studies 2004 ·Kidney International ·Hassane Izzedine,Jean‐Sébastien Hulot,Vincent Launay‐Vacher,(unknown),Stephanos J. Hadziyannis,G A Currie,Carol Brosgart,C. Westland,(unknown),Gilbert Deray	127
12	Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B 1 1The Adefovir Dipivoxil International 461 Study Group includes the following: N. Afdhal (Beth Israel Deaconess Medical Center, Boston, MA); P. Angus (Austin and Repatriation Medical Centre, Melbourne, Australia); Y. Benhamou (Hopital La Pitie Salpetriere, Paris, France); M. Bourliere (Hopital Saint Joseph, Marseille, France); P. Buggisch (Universitaetsklinikum Eppendorf, Department of Medicine, Hamburg, Germany); P. Couzigou (Hopital Haut Leveque, Pessac, France); P. Ducrotte and G. Riachi (Hopital Charles Nicolle, Rouen, France); E. Jenny Heathcote (Toronto Western Hospital, Toronto, Ontario, Canada); H. W. Hann (Jefferson Medical College, Philadelphia, PA); I. Jacobson (New York Presbyterian Hospital, New York, NY); K. Kowdley (University of Washington Hepatology Center, Seattle, WA); P. Marcellin (Hopital Beaujon, Clichy, France); P. Martin (Cedars-Sinai Medical Center, Los Angeles, CA); J. M. Metreau (Centre Hospitalier Universitaire Henri Mondor, Creteil, France); M. G. Peters (University of California, San Francisco, San Francisco, CA); R. Rubin (Piedmont Hospital, Atlanta, GA); S. Sacks (Viridae Clinical Sciences, Inc., Vancouver, Canada); H. Thomas (St. Mary’s Hospital, London, England); C. Trepo (Hopital Hôtel Dieu, Lyon, France); D. Vetter (Hopital Civil, Strasbourg, France); C. L. Brosgart, R. Ebrahimi, J. Fry, C. Gibbs, K. Kleber, J. Rooney, M. Sullivan, P. Vig, C. Westland, M. Wulfsohn, and S. Xiong (Gilead Sciences, Inc., Foster City, CA); D. F. Gray (GlaxoSmithKline, Greenford, Middlesex, England); R. Schilling and V. Ferry (Parexel International, Waltham, MA); and D. Hunt (Covance Laboratories, Princeton, NJ). 2003 ·Gastroenterology ·Marion G. Peters,Hie‐Won Hann,Paul Martin,E. Jenny Heathcote,Peter Buggisch,R Rubin,Marc Bourlière,Kris V. Kowdley,Christian Trépo,DF Gray,Mark Sullivan,K. Kleber,Ramin Ebrahimi,S. Xiong,Carol Brosgart	440
13	Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis Bbreakdown → 2003 ·New England Journal of Medicine ·Patrick Marcellin,Ting‐Tsung Chang,Seng Gee Lim,Myron J. Tong,William Sievert,Mitchell L. Shiffman,Lennox J. Jeffers,Zachary Goodman,Michael Wulfsohn,Shelly Xiong,John Fry,Carol Brosgart	1010
14	Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1 1Gilead Sciences gratefully acknowledges the patients, investigators, and study site personnel who participated in clinical trials GS-98-437 and GS-98-438. 2003 ·Gastroenterology ·C. Westland,William E. Delaney,Huiling Yang,Shanshan Chen,Patrick Marcellin,Stephanos J. Hadziyannis,Robert G. Gish,John Fry,Carol Brosgart,Craig S. Gibbs,Michael D. Miller,Shelly Xiong	185
15	Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks 2002 ·Hepatology ·Huiling Yang,Christopher Westland,William E. Delaney,E. Jenny Heathcote,Victoria Ho,John Fry,Carol Brosgart,Craig S. Gibbs,Michael D. Miller,Shelly Xiong	132
16	HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients 2002 ·AIDS ·Judith Falloon,Mounir Ait‐Khaled,Deborah A. Thomas,Carol Brosgart,Joseph J. Eron,Judith Feinberg,Timothy Flanigan,Scott M. Hammer,(unknown),Robert L. Murphy,(unknown),Henry Masur	31
17	GS-98-437 a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for the treatment of patients with HBeAg+ chronic hepatitis B infection: 48 week results. 2001 ·Hepatology ·Patrick Marcellin,Ting‐Tsung Chang,Seng Gee Lim,Myron J. Tong,William Sievert,Mitchell L. Shiffman,Lennox J. Jeffers,(unknown),Jia Ma,(unknown),John Fry,Carol Brosgart	13
18	Clinical Experience and Choice of Drug Therapy for Human Immunodeficiency Virus Disease 1999 ·Clinical Infectious Diseases ·Carol Brosgart,Thomas F. Mitchell,Rebecca Coleman,(unknown),Kathryn E. Stephenson,(unknown)	37
19	Randomized, Placebo-Controlled Trial of Rifampin, Ethambutol, and Ciprofloxacin for AIDS Patients with Disseminated Mycobacterium avium Complex Infection 1993 ·The Journal of Infectious Diseases ·Mark Z. Jacobson,D M Yajko,Donald W. Northfelt,Edwin D. Charlebois,(unknown),Carol Brosgart,C A Sanders,W K Hadley	44
20	Clofazimine as Prophylaxis for Disseminated Mycobacterium avium Complex Infection in AIDS 1993 ·The Journal of Infectious Diseases ·Donald I. Abrams,(unknown),Carroll Child,Stephen Shiboski,Carol Brosgart,(unknown)	20

About Carol Brosgart

Carol Brosgart is a scholar working on Hepatology, Epidemiology and Infectious Diseases, having authored 89 papers that have together received 7.8k indexed citations. Recurring topics across this work include Hepatitis B Virus Studies (75 papers), Hepatitis C virus research (73 papers) and Liver Disease Diagnosis and Treatment (35 papers). The work is most often cited by research in Hepatology (6.9k citations), Epidemiology (7.3k citations) and Infectious Diseases (1.6k citations). Carol Brosgart has collaborated with scholars based in United States, France and Canada. Frequent co-authors include Shelly Xiong, Patrick Marcellin, Seng Gee Lim, Zachary Goodman, John Fry, Stephanos J. Hadziyannis, Michael Wulfsohn, E. Jenny Heathcote, G. Kitis and Ting‐Tsung Chang. Their work appears in journals such as New England Journal of Medicine, The Lancet and Gastroenterology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact